# Effect of Vanzacaftor/Tezacaftor/Deutivacaftor (VNZ/TEZ/D-IVA) on the PK of Rosuvastatin in Healthy Participants

> **NCT07349394** · PHASE1 · COMPLETED · sponsor: **Vertex Pharmaceuticals Incorporated** · enrollment: 18 (actual)

## Conditions studied

- Cystic Fibrosis

## Interventions

- **DRUG:** VNZ/TEZ/D-IVA
- **DRUG:** Rosuvastatin

## Key facts

- **NCT ID:** NCT07349394
- **Lead sponsor:** Vertex Pharmaceuticals Incorporated
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2026-01-12
- **Primary completion:** 2026-02-28
- **Final completion:** 2026-03-12
- **Target enrollment:** 18 (ACTUAL)
- **Last updated:** 2026-04-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07349394

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07349394, "Effect of Vanzacaftor/Tezacaftor/Deutivacaftor (VNZ/TEZ/D-IVA) on the PK of Rosuvastatin in Healthy Participants". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT07349394. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*